A DIRECT MEASUREMENT OF SR-89 ACTIVITY IN BONE METASTASES

被引：16

作者：

BENJOSEF, E

MAUGHAN, RL

VASAN, S

PORTER, AT

机构：

[1] Department of Radiation Oncology, Harper Hospital, Detroit, MI, 48201

[2] Department of Radiation Oncology, Camden-Clark Memorial Hospital, Parksburg, WV

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1995年 / 16卷 / 06期

关键词：

D O I：

10.1097/00006231-199506000-00006

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The total absorbed dose after systemic administration of Sr-89 has been determined by measuring directly its activity in bone metastases. Autoradiography was performed on sections of bones obtained from patients treated with Sr-89 to study the pattern of deposition. Discs of 5 and 8 mm diameter were cut from metastatic sites and normal bone. The beta-ray activity was determined with a scintillation counter, which was calibrated using similar bovine cancellous bone discs, onto which a known activity of Sr-89 was transferred by pipette. From the activity measured, the initial activity (at the time of Sr-89 administration) was calculated. The absorbed dose was estimated using the methodology described in NCRP Report No. 58. The estimated initial activity of Sr-89 in the bone metastases varied from 2.3 to 240 MBq kg(-1), with a mean value of 31 +/- 27 MBq kg(-1). The total absorbed dose ranged from 1.3 to 64 Gy, with a mean of 18 +/- 16 Gy. The average total dose to normal bone sites was 1.1 +/- 0.4 Gy. The metastases to normal bone dose ratio in individual samples varied from 8 +/- 4 to 40 +/- 25. These estimates are in agreement with those obtained previously by indirect methods.

引用

页码：452 / 456

页数：5

共 12 条

[1]

Firusian N., Mellin P., Schmidt C.G., Results in strontium- 89 therapy in patients with carcinoma of the prostate and incurable pain from metastases: A preliminary report, J Urol, 116, pp. 764-768, (1976)

[2]

Laing A.H., Ackery D.M., Bayly R.J., Et al., Strontium-89 chloride for pain palliation in prostatic skeletal malignancy, Br I Radiol, 64, pp. 816-822, (1991)

[3]

Lewington V.J., Mc Ewan A.J., Ackery D.M., Et al., A prospective randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone, Eur J Cancer, 27, pp. 954-958, (1991)

[4]

Porter A.T., Mc Ewan A., Powe J.E., Et al., Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer, Int J Radiat Oncol Biol Plys, 25, pp. 805-813, (1993)

[5]

Robinson R.G., Spicer J.A., Preston D.F., Wegst A.V., Martin N.L., Treatment of metastatic bone pain with strontium-89, Nucl Med Biol, 14, pp. 219-222, (1987)

[6]

Silberstein E.B., Williams C., Strontium-89 therapy for the pain of osseous metastases, J Nucl Med, 26, pp. 345-348, (1985)

[7]

Tennvall J., Darte L., Lindgren R., El Hassan A.M., Palliation of multiple bony metastases from prostatic carcinoma with strontium-89, Acta Oncol, 27, pp. 365-369, (1988)

[8]

Blake G.M., Zivanovic M.A., Mc ewan A.J., Et al., Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the pros¬tate, Eur I Nucl Med, 12, pp. 447-454, (1986)

[9]

Blake G.M., Zivanovic M.A., Mc ewan A.J., Et al., Strontium-89 therapy: Strontium kinetics and dosimetry in two patients treated for metastasizing osteosarcoma, Br J Radiol, 60, pp. 253-259, (1987)

[10]

Breen S.L., Powe J.E., Porter A.T., Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma, J Nucl Med, 33, pp. 1316-1323, (1992)

← 1 2 →